Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Elsulfavirine in Healthy Subjects
NCT05165550Phase 1Completed
- Sponsor
- Viriom Inc
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elsufavirine in human immunodeficiency virus type 1 infection (HIV-1) (3 cohorts), sponsored by Viriom Inc. Primary endpoints: Incidence of Adverse Events at 35 days and Incidence of Serious Adverse Events at 35 days. Started Apr 2022; status: completed.
02
Drugs
elsufavirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05165550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05165550.